Safety and efficacy of aprepitant for chemotherapy‐induced nausea and vomiting in pediatric patients: A prospective, observational study

Megan Bodge, Alexandra Shillingburg, Stephan Paul, Lisa Biondo

Pediatric Blood & Cancer · 2013 · 22 citations · 9 references

Concepts

Abstract

Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months-17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%.

References

9